SCHEMBL2835335

SCHEMBL2835335

CCOC(=O)c1cc(N)n(-c2ccccc2)n1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.65
GAA P10253 1/20 0.65
MAPT P10636 4/20 0.61
PDE4D Q08499 1/20 0.59
TP53 P04637 3/20 0.59
ALDH1A1 P00352 3/20 0.59
HPGD P15428 2/20 0.59
KDM4E B2RXH2 1/20 0.59
HSD17B10 Q99714 1/20 0.59
POLB P06746 1/20 0.58
MEN1 O00255 1/20 0.58
RXFP1 Q9HBX9 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
CA9 Q16790 1/20 0.58
THRB P10828 1/20 0.57
LMNA P02545 1/20 0.57
ADORA2A P29274 1/20 0.56
ADORA1 P30542 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14357202 0.89 CA9 (0.61) KMT2AGAAMAPTPDE4DTP53
SCHEMBL14357218 0.88 KMT2A (0.55) KMT2AGAAMAPTPDE4DTP53
SCHEMBL4701523 0.86 CHRNA7 (0.62) KMT2AGAAMAPTPDE4DTP53
SCHEMBL11656484 0.86 CHRNA7 (0.62) KMT2AGAAMAPTPDE4DTP53
SCHEMBL16517015 0.86 KMT2A (0.50) KMT2AGAAMAPTPDE4DTP53
SCHEMBL3299372 0.86 KMT2A (0.68) KMT2AGAAMAPTPDE4DTP53
SCHEMBL7268 0.86 KMT2A (0.68) KMT2AGAAMAPTPDE4DTP53
SCHEMBL4703884 0.85 PDE4D (0.62) KMT2AGAAMAPTPDE4DTP53
SCHEMBL17239452 0.85 BCHE (0.53) KMT2AGAAMAPTTP53ALDH1A1
SCHEMBL28625965 0.84 KMT2A (0.67) KMT2AGAAMAPTPDE4DTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473285-B2 DCN-1 modulating compounds and methods of use thereof CELLARITY, INC. (US) 2025-11-18 US disclosed
US-20250257063-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF THAMES PHARMA PARTNERS 2025-08-14 US disclosed
US-20250163057-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF THAMES PHARMA PARTNERS 2025-05-22 US disclosed
WO-2025096956-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF CELLARITY, INC. (US) 2025-05-08 WO disclosed
WO-2023055952-A1 NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) DEGRADING COMPOUNDS C4 THERAPEUTICS, INC. (US) 2023-04-06 WO disclosed
CN-108329246-B Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors 阵列生物制药公司 2021-02-26 CN disclosed
US-10889589-B2 Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain ARRAY BIOPHARMA INC. (US) 2021-01-12 US disclosed
US-20190270749-A1 BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN ARRAY BIOPHARMA INC. (US) 2019-09-05 US disclosed
US-10351575-B2 Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain ARRAY BIOPHARMA INC. (US) 2019-07-16 US disclosed
US-10323022-B2 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-06-18 US disclosed
EP-1732934-A1 NOVEL THIAZOLOPYRAZOLES AND METHODS OF THEIR USE Lexicon Genetics Incorporated (US) 2006-12-20 EP disclosed
US-20060281733-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. 2006-12-14 US disclosed
EP-1635821-A2 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES Elan Pharmaceuticals, Inc. (US) 2006-03-22 EP disclosed
EP-1633348-A1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES Elan Pharmaceuticals, Inc. (US) 2006-03-15 EP disclosed
US-20050282874-A1 Novel thiazolopyrazoles and methods of their use OXFORD FINANCE LLC, AS COLLATERAL AGENT 2005-12-22 US disclosed
WO-2005095420-A1 NOVEL THIAZOLOPYRAZOLES AND METHODS OF THEIR USE LEXICON GENETICS, INC (US) 2005-10-13 WO disclosed
US-20050032868-A1 Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists ELAN PHARMACEUTICALS, INC. 2005-02-10 US disclosed
US-20050020659-A1 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists ELAN PHARMACEUTICALS, INC. 2005-01-27 US disclosed
WO-2004098589-A1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES ELAN PHARMACEUTICALS, INC. (US) 2004-11-18 WO disclosed
WO-2004099155-A2 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES ELAN PHARMACEUTICALS, INC. (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12473285-B2 DCN-1 modulating compounds and methods of use thereof DCUN1D1, DCUN1D2, DCUN1D4 KMT2A 4381/4885GAA 2694/4885MAPT 4352/4885
US-20190270749-A1 BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN TK1, UACA, TDP1 KMT2A 3789/4885GAA 2456/4885MAPT 464/4885
US-20050282874-A1 Novel thiazolopyrazoles and methods of their use CYP11B2, CYP11B1, TPMT KMT2A 3018/4885GAA 307/4885MAPT 1009/4885
US-20050020659-A1 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists BDKRB1, BDKRB2, BRS3 KMT2A 3940/4885GAA 4207/4885MAPT 2597/4885
US-10323022-B2 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors RET, TK1, DSTYK KMT2A 3907/4885GAA 2073/4885MAPT 118/4885
US-20050032868-A1 Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists BDKRB1, BDKRB2, BRS3 KMT2A 4030/4885GAA 4254/4885MAPT 2669/4885
US-20250163057-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF DCUN1D1, DCUN1D2, DCUN1D4 KMT2A 4381/4885GAA 2694/4885MAPT 4352/4885
US-10889589-B2 Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain TK1, UACA, TDP1 KMT2A 3789/4885GAA 2456/4885MAPT 464/4885
US-20060281733-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases BDKRB1, BDKRB2, CNR1 KMT2A 2589/4885GAA 3468/4885MAPT 3561/4885
US-20250257063-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF DCUN1D1, DCUN1D2, DCUN1D4 KMT2A 4381/4885GAA 2694/4885MAPT 4352/4885
US-10351575-B2 Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain TK1, UACA, TDP1 KMT2A 3789/4885GAA 2456/4885MAPT 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.